The Cost-Sharing Solution: The New NICE Ticket

J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim?

By Melanie Senior

The pharmaceutical industry’s relationship with the UK’s National Institute for Clinical Excellence started out as a black and white proposition:...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet